CompareMarketResearchRequest a sample
Home / Healthcare / Extended-Action Local Anaesthetic

Healthcare · Market report

Extended-Action Local Anaesthetic Market Size, Share and Forecast 2026-2036

The global extended-action local anaesthetic market is worth USD 684 mn in 2026 and is forecast to reach USD 1.4 bn by 2036, growing at a 7.5% CAGR. United States is the largest country market and Liposomal bupivacaine is the largest by product segment.

USD 684 mnMarket size 2026
USD 1.4 bnForecast 2036
7.5%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global extended-action local anaesthetic market is worth USD 684 mn in 2026 and is forecast to reach USD 1.4 bn by 2036, growing at a 7.5% CAGR. United States is the largest country market and Liposomal bupivacaine is the largest by product segment.

ScopeLong-acting local anaesthetics that give 24 to 72 hours of post-surgical pain relief from a single dose, including liposomal bupivacaine, extended-release bupivacaine and bupivacaine implants.
IndustryHealthcare
Value 2025USD 630 mn
Value 2026USD 684 mn
Value 2036USD 1.4 bn
CAGR 2026-20367.5%
Volume 20263.44 million doses
Volume 20366.41 million doses
Average price 2026USD 199 per dose
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Extended-Action Local Anaesthetic market size and forecast, 2026-2036

Exhibit 1The global extended-action local anaesthetic market is forecast to grow from USD 684 mn in 2026 to USD 1.4 bn by 2036, more than doublingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 7.5%
Extended-Action Local Anaesthetic market value, 2025 to 2036Market value by year. 2025: USD 630.0 mn; 2026: USD 683.5 mn; 2027: USD 734.8 mn; 2028: USD 789.9 mn; 2029: USD 849.2 mn; 2030: USD 912.9 mn; 2031: USD 981.3 mn; 2032: USD 1.05 bn; 2033: USD 1.13 bn; 2034: USD 1.22 bn; 2035: USD 1.31 bn; 2036: USD 1.41 bn. Compound annual growth rate 2026 to 2036: 7.5%.2025683.5 mn2026981.3 mn20311.41 bn20367.5% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 683.5 mn
2027USD 734.8 mn
2028USD 789.9 mn
2029USD 849.2 mn
2030USD 912.9 mn
2031USD 981.3 mn
2032USD 1.05 bn
2033USD 1.13 bn
2034USD 1.22 bn
2035USD 1.31 bn
2036USD 1.41 bn

Extended-Action Local Anaesthetic market segmentation

By product

Exhibit 2Liposomal bupivacaine is the largest segment by product, with 86.0% of 2026 revenueEstimated share of 2026 global revenue, by product
Extended-Action Local Anaesthetic market share by product, 2026Share of 2026 revenue by product. Liposomal bupivacaine: 86.0%; Extended-release bupivacaine and meloxicam: 9.0%; Bupivacaine implants and others: 5.0%.Liposomal bupivacaine86.0%Extended-release bupivacaine and meloxicam9.0%Bupivacaine implants and others5.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Liposomal bupivacaine86.0%45.4%USD 588 mn0.8%
Extended-release bupivacaine and meloxicam9.0%50.9%USD 62 mn27.8%
Bupivacaine implants and others5.0%3.6%USD 34 mn4.2%

By setting

Exhibit 3Ambulatory surgery centres adds the most revenue by setting, growing from USD 287 mn in 2026 to USD 662 mn by 2036Estimated revenue in USD by setting, 2026 and 2036 forecast
Extended-Action Local Anaesthetic market by setting, 2026 and 2036Revenue by setting in 2026 and 2036. Ambulatory surgery centres: USD 287 mn in 2026, USD 662 mn in 2036, change +131%; Hospitals: USD 342 mn in 2026, USD 626 mn in 2036, change +83%; Specialty surgical hospitals: USD 55 mn in 2026, USD 121 mn in 2036, change +120%.20262036 forecastChangeAmbulatory surgery centres+131%287 mn662 mnHospitals+83%342 mn626 mnSpecialty surgical hospitals+120%55 mn121 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Hospitals50.0%44.4%USD 342 mn6.2%
Ambulatory surgery centres42.0%47.0%USD 287 mn8.7%
Specialty surgical hospitals8.0%8.6%USD 55 mn8.2%

By surgery

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Orthopaedic46.0%44.1%USD 314 mn7.0%
General and abdominal24.0%24.1%USD 164 mn7.5%
Cardiothoracic and plastic18.0%19.8%USD 123 mn8.5%
Other surgery12.0%12.0%USD 82 mn7.5%

By administration

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Surgical-site infiltration52.0%46.0%USD 355 mn6.2%
Peripheral nerve block34.0%38.0%USD 232 mn8.7%
Epidural and implant-based14.0%16.0%USD 96 mn8.9%

By payer

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Commercial insurance52.0%50.0%USD 355 mn7.1%
Medicare36.0%38.0%USD 246 mn8.1%
Medicaid and self-pay12.0%12.0%USD 82 mn7.5%

Top 25 countries for extended-action local anaesthetic by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 98.7% of 2026 revenue and the 25 countries below together hold 99.6%.

Exhibit 4United States is the largest country market at USD 649 mn in 2026, and the three largest countries hold 96.8% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Extended-Action Local Anaesthetic market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 649 mn, 95.0%; Germany: USD 6.8 mn, 1.0%; United Kingdom: USD 5.5 mn, 0.8%; France: USD 3.4 mn, 0.5%; Spain: USD 2.0 mn, 0.3%; Italy: USD 2.0 mn, 0.3%; Japan: USD 1.4 mn, 0.2%; Canada: USD 1.4 mn, 0.2%; Australia: USD 1.4 mn, 0.2%; Netherlands: USD 1.4 mn, 0.2%.United States649 mn 95.0%Germany6.8 mn 1.0%United Kingdom5.5 mn 0.8%France3.4 mn 0.5%Spain2.0 mn 0.3%Italy2.0 mn 0.3%Japan1.4 mn 0.2%Canada1.4 mn 0.2%Australia1.4 mn 0.2%Netherlands1.4 mn 0.2%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 649 mn95.0%USD 1.3 bn7.3%
2GermanyUSD 6.8 mn1.0%USD 21 mn11.9%
3United KingdomUSD 5.5 mn0.8%USD 17 mn11.9%
4FranceUSD 3.4 mn0.5%USD 9.9 mn11.2%
5SpainUSD 2.0 mn0.3%USD 5.6 mn10.6%
6ItalyUSD 2.0 mn0.3%USD 5.6 mn10.6%
7JapanUSD 1.4 mn0.2%USD 4.2 mn11.9%
8CanadaUSD 1.4 mn0.2%USD 4.2 mn11.9%
9AustraliaUSD 1.4 mn0.2%USD 4.2 mn11.9%
10NetherlandsUSD 1.4 mn0.2%USD 4.2 mn11.9%
11ChinaUSD 0.82 mn0.1%USD 2.1 mn9.9%
12BrazilUSD 0.48 mn0.07%USD 1.1 mn8.9%
13SwitzerlandUSD 0.48 mn0.07%USD 0.85 mn5.9%
14BelgiumUSD 0.48 mn0.07%USD 0.85 mn5.9%
15SwedenUSD 0.48 mn0.07%USD 0.85 mn5.9%
16South KoreaUSD 0.48 mn0.07%USD 1.1 mn8.9%
17AustriaUSD 0.41 mn0.06%USD 0.70 mn5.6%
18DenmarkUSD 0.41 mn0.06%USD 0.70 mn5.6%
19IsraelUSD 0.41 mn0.06%USD 0.70 mn5.6%
20Saudi ArabiaUSD 0.41 mn0.06%USD 0.85 mn7.5%
21IrelandUSD 0.27 mn0.04%USD 0.56 mn7.5%
22NorwayUSD 0.27 mn0.04%USD 0.56 mn7.5%
23MexicoUSD 0.27 mn0.04%USD 0.70 mn9.9%
24United Arab EmiratesUSD 0.27 mn0.04%USD 0.70 mn9.9%
25IndiaUSD 0.27 mn0.04%USD 0.85 mn11.9%
Rest of worldUSD 2.7 mn0.4%USD 5.1 mn6.6%
Exhibit 5United States and Germany account for 94% of the USD 725 mn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Extended-Action Local Anaesthetic market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 684 mn. United States: +USD 665 mn; Germany: +USD 14 mn; United Kingdom: +USD 11 mn; France: +USD 6.4 mn; Spain: +USD 3.6 mn; 20 other countries: +USD 22 mn; Rest of world: +USD 2.4 mn. Market value 2036: USD 1.4 bn.Market value 2026684 mnUnited States+665 mnGermany+14 mnUnited Kingdom+11 mnFrance+6.4 mnSpain+3.6 mn20 other countries+22 mnRest of world+2.4 mnMarket value 20361.4 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Pacira BioSciences
  • Heron Therapeutics
  • Innocoll Pharmaceuticals

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the extended-action local anaesthetic market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 7.5% is calculated from the resulting values.

The market is divided by product, by setting, by surgery, by administration, by payer. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the extended-action local anaesthetic market?

The global extended-action local anaesthetic market is estimated at USD 630 mn in 2025 and USD 684 mn in 2026.

How fast will the extended-action local anaesthetic market grow?

It is forecast to reach USD 1.4 bn by 2036, a compound annual growth rate of 7.5% from 2026, an increase of USD 725 mn.

Which country is the largest market for extended-action local anaesthetic?

United States is the largest market by revenue at USD 649 mn in 2026, 95.0% of the global total. The three largest countries together hold 96.8%.

Which country is growing fastest?

Among the ten largest markets, Germany is growing fastest at 11.9% a year from 2026 to 2036.

Which extended-action local anaesthetic segment is largest?

In the by product split, Liposomal bupivacaine is the largest segment with 86.0% of 2026 revenue.

Who are the leading extended-action local anaesthetic companies?

Global leaders include Pacira BioSciences, Heron Therapeutics, Innocoll Pharmaceuticals.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Epilepsy Monitoring Devices Extracorporeal Membrane Oxygenation Machine →

All Healthcare markets →

Request a sample